Sign In

John Carroll

Founded Endpoints News -- 201,000 subscribers -- invented FierceBiotech. 46 years in journalism -- 21 of that in biopharma.

John Carroll is a prominent figure in the biopharma world with a profound impact as the Founder and Editor-in-Chief of Endpoints News, a leading publication with a loyal global subscriber base of over 108,000 individuals.

He holds a Bachelor's degree in Political Science and History from Tufts University, providing a strong academic foundation for his career in journalism and the biopharmaceutical industry.

With a rich professional background, John has held key editorial positions at renowned publications such as FierceBiotech, Managed Care magazine, and the Dallas Business Journal.

Additionally, he has broadened his experience through roles including a contributing editor at Managed Care magazine, a freelancer at TexasWriters, and a reporter at the Kansas City Star & Times.

John Carroll's expertise and influence are evident through his work across various media outlets, making him a well-respected and knowledgeable individual in the field of biopharma journalism.

Highlights

Oct 14 · twitter

I think a broader understanding of market realities is badly needed. For a lot of patients, the cavalry isn't coming.

Oct 14 · twitter

Interesting piece from Lei Lei Wu on Jim Wilson's rethink on gene therapies for ultra-rare diseases. We can cure some awful diseases, but they don't make money. Trying to use the prospect of PRVs as an enticement is a non-starter. Right now, more than ever before, telling a pharma they could make a hundred million or three off of a drug for a rare disease breakthrough would get you a quick exit. Cures like this are nothing but a costly distraction to the major players. There has to be a whole new business model for these drugs, or some open source approach for manufacturing. Big, chronic conditions are where the money is. Remember that the next time you hear how "it's all about patients." https://t.co/FQW14AX0VL

John Carroll
Add to my network

Location

Dorset, Vermont, United States